O
OncoSTING
OncoSTING is developing novel bladder cancer therapies that enhance the efficacy of standard Bacillus Calmette-Guérin (BCG) immunotherapy. The company aims to improve patient outcomes by increasing the therapeutic response in individuals with bladder cancer.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$256KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- OncoSTING is developing novel bladder cancer therapies that enhance the efficacy of standard Bacillus Calmette-Guérin (BCG) immunotherapy. The company aims to improve patient outcomes by increasing the therapeutic response in individuals with bladder cancer.